Biovica receives second work order from leading global pharmaceutical company under expanded master agreement
Biovica, a company specializing in blood-based cancer monitoring, today announces a second work order under its recently expanded Master Services Agreement with one of the world's leading pharmaceutical companies. The order covers a new oncology program and follows the first work order of approximately USD 100, 000, announced on July 20th, 2026.
This new work order is valued at approximately USD 150,000 (about SEK 1.4 million) and covers DiviTum® TKa testing in a program focused on cancer cell-cycle regulation. The study is expected to start in January 2027 and run for approximately 24 months, with revenue recognized as samples are analyzed.
Testing will be performed at Biovica's CLIA-certified laboratory in San Diego, California. The results support pharmacodynamic assessment of drug activity and of changes in cell proliferation during treatment.
"A second order from the same customer, for a new program, is the pattern we want to see in Pharma Services: customers who have used DiviTum® TKa once bring it into their next study. Growing with the sponsors we already serve is the first step in building this business," said Theis Kipling, CEO of Biovica.